Anti-inflammatory role of fetuin-A in injury and infection

Current Molecular Medicine

Volumn 12, Issue 5, 2012, Pages 625-633

  Wang, H ^a   Sama, A E ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Acute phase protein; Cerebral ischemic injury; DAMP; Endotoxemia; HMGB1; Innate immune cells; PAMP; Sepsis

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACUTE PHASE PROTEIN; CARRAGEENAN; FETUIN A; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; NICOTINIC RECEPTOR; OPSONIN; SPERMINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; ENDOTOXEMIA; GASTROINTESTINAL TRACT; HUMAN; INFECTION; INJURY; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREATITIS; PAW EDEMA; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; SEPSIS; TISSUE INJURY;

MUS;

EID: 84860995244     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800620039     Document Type: Article

References (134)

1. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through tolllike receptors. Science 1999; 285(5428): 732-736.
2. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282(5396): 2085-2088.
3. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408(6813): 740-745.
4. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192(4): 565-570.
5. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323(5922): 1722-1725.
6. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
7. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425): 248-251.
8. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330(6149): 662-664.
9. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12(11): 404-410.
10. Heinzel FP. The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 1990; 145(9): 2920-2924.
11. Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110(6): 1970-1981.
12. Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent echanism. J Immunol 2003; 170(7): 3890-3897.
13. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418(6894): 191-195.
14. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009; 13(6): R174.
15. Park JS, Svetkauskaite D, He Q, et al. Involvement of TLR 2 and TLR 4 in cellular activation by high mobility group box 1 protein (HMGB1). J Biol Chem 2004; 279(9): 7370-7377.
16. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26(2): 174-179.
17. Dai S, Sodhi C, Cetin S, et al. Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of Toll-like receptor-4 and increased cell-matrix adhesiveness. J Biol Chem 2010; 285(7): 4995-5002.
18. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290(3): C917-C924.
19. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61(1): 1-9.
20. Pedrazzi M, Patrone M, Passalacqua M, et al. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 2007; 179(12): 8525-8532.
21. Yamoah K, Brebene A, Baliram R, et al. High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol Endocrinol 2008; 22(5): 1141-1153.
22. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101(7): 2652-2660.
23. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254(4): 375-385.
24. Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F. High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost 2009; 102(2): 352-359.
25. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81(1): 59-66.
26. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere- Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81(1): 84-91.
27. Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007; 26(4): 1129-1139.
28. Zhu S, Ashok M, Li J, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009; 15(7-8): 275-282.
29. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101(1): 296-301.
30. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001; 164(10): 1768-1773.
31. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosismediated sepsis lethality. J Exp Med 2006; 203(7): 1637-1642.
32. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99(19): 12351-12356.
33. Chen G, Li J, Qiang X, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 2005; 46(4): 623-627.
34. Wang H, Li W, Li J, et al. The Aqueous Extract of a Popular Herbal Nutrient Supplement, Angelica sinensis, Protects Mice against Lethal Endotoxemia and Sepsis. J Nutr 2006; 136(2): 360-365.
35. Li W, Ashok M, Li J, Yang H, Sama AE, Wang H. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS ONE 2007; 2(11): e1153.
36. Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10(11): 1216-1221.
37. Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. Nat Med 2004; 10(2): 124-125.
38. Pavlov VA, Ochani M, Yang LH, et al. Selective alpha7- nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 2007; 35(4): 1139-1144.
39. Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, et al. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol Med 2008; 14(9-10): 567-574.
40. Matthay MA, Ware LB. Can nicotine treat sepsis? Nat Med 2004; 10(11): 1161-1162.
41. O'Connor KA, Hansen MK, Rachal PC, et al. Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine 2003; 24(6): 254-265.
42. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123(3): 790-802.
43. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165(6): 2950-2944.
44. Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004; 170(12): 1310-1316.
45. Lin X, Yang H, Sakuragi T, et al. {alpha}-Chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol 2005; 289(4): L583-L590.
46. Rowe SM, Jackson PL, Liu G, et al. Potential role of high mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008; 178(8): 822-831.
47. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004; 255(3): 320-331.
48. Wang H, Zhu S, Zhou R, Li W, Sama AE. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 2008; 10: e32.
49. Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009; 32(4): 348-357.
50. Taylor CP, Meldrum BS. Na+ channels as targets for neuroprotective drugs. Trends Pharmacol Sci 1995; 16(9): 309-316.
51. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999; 399 Supplement: A7-A14.
52. Feuerstein GZ, Wang X, Barone FC. The role of cytokines in the neuropathology of stroke and neurotrauma. Neuroimmunomodulation 1998; 5(3-4): 143-159.
53. Meldrum B. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc Brain Metab Rev 1990; 2(1): 27-57.
54. Kato H, Kogure K, Liu XH, Araki T, Itoyama Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res 1996; 734(1-2): 203-212.
55. Botchkina GI, Meistrell ME, Botchkina IL, Tracey KJ. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med 1997; 3(11): 765-781.
56. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996; 27(10): 1739-1743.
57. Buttini M, Appel K, Sauter A, Gebicke-Haerter PJ, Boddeke HW. Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience 1996; 71(1): 1-16.
58. Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand 2001 Nov;104(5):288-295 104(5):288-295.
59. Meistrell ME, Botchkina GI, Wang H, et al. Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock 1997; 8(5): 341-348.
60. Bertorelli R, Adami M, Di Santo E, Ghezzi P. MK 801 and dexamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerebral ischemia in the rat brain. Neurosci Lett 1998; 246(1): 41-44.
61. Barone FC, Arvin B, White RF, et al. Tumor necrosis factoralpha. A mediator of focal ischemic brain injury. Stroke 1997; 28(6): 1233-1244.
62. Yang GY, Gong C, Qin Z, Liu XH, Lorris BA. Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. Brain Res Mol Brain Res 1999; 69(1): 135-143.
63. Qiu J, Nishimura M, Wang Y, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008; 28(5): 927-938.
64. Zhang J, Takahashi HK, Liu K, et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 2011; 42(5): 1420-1428.
65. Yang QW, Lu FL, Zhou Y, et al. HMBG1 mediates ischemiareperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 2011; 31(2): 593-605.
66. Muhammad S, Barakat W, Stoyanov S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008; 28(46): 12023-12031.
67. Rosas-Ballina M, Olofsson PS, Ochani M, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334(6052): 98-101.
68. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve timulation attenuates the systemic inflammatory response to ndotoxin. Nature 2000; 405(6785): 458-42.
69. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of nflammation. Nature 2003; 421(6921): 384-38
70. Huston JM, Gallowitsch-Puerta M, Ochani M, et al. ranscutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine epsis. Crit Care Med 2007; 35(12): 2762-276
71. Su X, Matthay MA, Malik AB. Requisite role of the cholinergic lpha7 nicotinic acetylcholine receptor pathway in uppressing Gram-negative sepsis-induced acute lung nflammatory injury. J Immunol 2010; 184(1): 401-440.
72. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gammainduced ctivation. Proc Natl Acad Sci USA 1992; 89(18): 676-660.
73. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation y interleukin 10. J Exp Med 1991; 174(6): 1549-1555.
74. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, amilton JA. Potential antiinflammatory effects of interleukin: suppression of human monocyte tumor necrosis factor lpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86(10): 3803-3807.
75. Paschen W. Polyamine metabolism in reversible cerebral ischemia. Cerebrovasc Brain Metab Rev 1992; 4(1): 59-88.
76. Zhang M, Caragine T, Wang H, et al. Spermine inhibits roinflammatory cytokine synthesis in human mononuclear ells: a counterregulatory mechanism that restrains the immune response. J Exp Med 1997; 185(10): 1759-1759.
77. Zhang M, Borovikova LV, Wang H, Metz C, Tracey KJ. Spermine inhibition of monocyte activation and inflammation. Mol Med 1999; 5(9): 595-605.
78. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. etuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 1998; 95[24): 14429-14434.
79. Zhang M, Wang H, Tracey KJ. Regulation of macrophage ctivation and inflammation by spermine: a new chapter in an ld story. Crit Care Med 2000; 28(4 Suppl): N60-N66.
80. Wang H, Zhang M, Soda K, Sama A, Tracey KJ. Fetuin protects the fetus from TNF [letter]. Lancet 1997; 350(9081):861-862.
81. Wang H, Tracey KJ. Fetuin opsonizes macrophagedeactivating ations. In: Marshall JC, Cohen J, editors. Update in Intensive Care and Emergency Medicine: Immune esponse in the Critically Ill. SpringerVerlag Press, 1999: 155-163.
82. Christie DL, Dziegielewska KM, Hill RM, Saunders NR. Fetuin: the bovine homologue of human alpha 2HS glycoprotein. FEBS Lett 1987; 214(1): 45-49.
83. Pedersen KO. Fetuin, a new globin isolated from serum. ature 1944; 154: 575.
84. Terkelsen OB, Jahnen-Dechent W, Nielsen H, et al. Rat etuin: distribution of protein and mRNA in embryonic and neonatal rat tissues. Anat Embryol (Berl) 1998; 197(2): 125-133.
85. Kitchener PD, Dziegielewska KM, Knott GW, et al. Fetuin xpression in the dorsal root ganglia and trigeminal ganglia of perinatal rats. Int J Dev Neurosci 1997; 15(6): 717-727.
86. Dziegielewska KM, Daikuhara Y, Ohnishi T, et al. Fetuin in he developing neocortex of the rat: distribution and origin. J omp Neurol 2000; 423(3): 373-388.
87. Kitchener PD, Dziegielewska KM, Hutton EJ, Hinrichsen CF, Saunders NR. Fetuin in neurons of the retina and cerebellum during fetal and postnatal development of the rat. Int J Dev Neurosci 1999; 17(1): 21-30.
88. Daveau M, Christian D, Julen N, Hiron M, Arnaud P, Lebreton JP. The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988; 241(1-2): 191-194.
89. Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS ONE 2011; 6(2): e16945.
90. Kusnierz-Cabala B, Gurda-Duda A, Panek J, et al. Serum fetuin A concentrations in patients with acute pancreatitis. Clin Lab 2010; 56(5-6): 191-195.
91. Metry G, Stenvinkel P, Qureshi AR, Carrero JJ, Yilmaz MI, Barany P, Snaedal S, Heimburger O, Lindholm B, Suliman ME. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest 2008; 38(11):804-811.
92. Sato H, Kazama JJ, Wada Y, et al. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med 2007; 46(20):1685-1691.
93. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118(24): 2555-2562.
94. Tuttolomondo A, Di Raimondo D, Di Sciacca R, et al. Fetuin- A and CD40 L plasma levels in acute ischemic stroke: Differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis 2010; 208(1): 290-296.
95. Dziegielewska KM, Brown WM, Gould CC, Matthews N, Sedgwick JE, Saunders NR. Fetuin: an acute phase protein in cattle. J Comp Physiol [B] 1992; 162(2): 168-171.
96. Peltz ED, Moore EE, Eckels PC, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009; 32(1): 17-22.
97. Zhu S, Li W, Ward MF, Sama AE, Wang H. High mobility group box 1 protein as a potential drug target for infectionand injury-elicited inflammation. Inflamm Allergy Drug Targets 2010; 9(1): 60-72.
98. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117(10): 2847-2859.
99. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemiareperfusion. J Exp Med 2005; 201(7): 1135-1143.
100. Tsung A, Klune JR, Zhang X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204(12): 2913-2923.
101. Watanabe T, Kubota S, Nagaya M, et al. The role of HMGB- 1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 2005; 124(1): 59-66.
102. Wang H, Li W, Zhu S, et al. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J Cereb Blood Flow Metab 2010; 30(3): 493-504.
103. Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996; 739(1-2): 88-96.
104. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996; 271(22): 12755-12761.
105. Mathews ST, Srinivas PR, Leon MA, Grunberger G. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci 1997; 61(16): 1583-1592.
106. Haasemann M, Nawratil P, Muller-Esterl W. Rat tyrosine kinase inhibitor shows sequence similarity to human alpha 2- HS glycoprotein and bovine fetuin. Biochem J 1991; 274(Pt 3): 899-902.
107. Goustin AS, Abou-Samra AB. The thrifty gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal 2011; 23(6): 980-990
108. Ix JH, Wassel CL, Kanaya AM, et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008; 300(2): 182-188.
109. Szweras M, Liu D, Partridge EA, et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002; 277(22): 19991-19997.
110. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112(3): 357-366.
111. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a crosssectional study. Lancet 2003; 361(9360): 827-833.
112. Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circ Res 2011; 108(12): 1494-1509.
113. Heiss A, DuChesne A, Denecke B, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 278(15): 13333-13341.
114. Wu CY, Martel J, Young D, Young JD. Fetuin-A/albuminmineral complexes resembling serum calcium granules and putative nanobacteria: demonstration of a dual inhibitionseeding concept. PLoS One 2009; 4(11): e8058.
115. Rochette CN, Rosenfeldt S, Heiss A, Narayanan T, Ballauff M, Jahnen-Dechent W. A shielding topology stabilizes the early stage protein-mineral complexes of fetuin-A and calcium phosphate: a time-resolved small-angle X-ray study. Chembiochem 2009; 10(4): 735-740.
116. Wang H, Li W, Zhu S, Wang P, Sama AE. Role of Fetuin-A in Injury and Infection. Acute Phase Proteins: Regulation and Functions of Acute Phase Proteins. Intech Open Access Publisher, 2011: 329-344.
117. Dziegielewska KM, Andersen NA, Saunders NR. Modification of macrophage response to lipopolysaccharide by fetuin. Immunol Lett 1998; 60(1): 31-35.
118. Ombrellino M, Wang H, Yang H, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001; 15(3): 181-185.
119. Li J, Doyle KM, Tatlisumak T. Polyamines in the brain: distribution, biological interactions, and their potential therapeutic role in brain ischaemia. Curr Med Chem 2007; 14(17): 1807-1813.
120. Shirhan MD, Moochhala SM, Ng PY, et al. Spermine reduces infarction and neurological deficit following a rat model of middle cerebral artery occlusion: a magnetic resonance imaging study. Neuroscience 2004; 124(2): 299-304.
121. Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA, Jr. The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci USA 1998; 95(19):11140-11145.
122. Adibhatla RM, Hatcher JF, Sailor K, Dempsey RJ. Polyamines and central nervous system injury: spermine and spermidine decrease following transient focal cerebral ischemia in spontaneously hypertensive rats. Brain Res 2002; 938(1-2): 81-86.
123. Araneda RC, Lan JY, Zheng X, Zukin RS, Bennett MV. Spermine and arcaine block and permeate N-methyl-Daspartate receptor channels. Biophys J 1999; 76(6): 2899-2911.
124. Ferchmin PA, Perez D, Biello M. Spermine is neuroprotective against anoxia and N-methyl-D-aspartate in hippocampal slices. Brain Res 2000; 859(2): 273-29.
125. Ivanova S, Botchkina GI, Al-Abed Y, et al. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J Exp Med 1998; 188(2): 327-340.
126. Williams K. Modulation and block of ion channels: a new biology of polyamines. Cell Signal 1997; 9(1): 1-13.
127. Paschen W, Widmann R, Weber C. Changes in regional polyamine profiles in rat brains after transient cerebral ischemia (single versus repetitive ischemia): evidence for release of polyamines from injured neurons. Neurosci Lett 1992; 135(1): 121-124.
128. Zhu S, Ashok M, Li J, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009; 15(7-8): 275-282.
129. Li W, Zhu S, Li J, et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol 2011; 81(9): 1152-1163.
130. Chmiela M, Czkwianianc E, Wadstrom T, Rudnicka W. Role of Helicobacter pylori surface structures in bacterial interaction with macrophages. Gut 1997; 40(1): 20-24.
131. Dubreuil JD, Giudice GD, Rappuoli R. Helicobacter pylori interactions with host serum and extracellular matrix proteins: potential role in the infectious process. Microbiol Mol Biol Rev 2002; 66(4): 617-629.
132. Lord JM. A physiological role for alpha2-HS glycoprotein: stimulation of macrophage uptake of apoptotic cells. Clin Sci (Lond) 2003; 105(3): 267-268.
133. Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond) 2003; 105(3): 273-278.
134. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291(6): C1318-1325.